IPO Week Preview

October 21, 2026 | Week of October 19–23, 2026

By Frank Whitaker With staff and AI research assistance

Research timestamp: 2026-10-21 03:00 UTC

A date to watch, not a promise

The U.S. calendar has narrowed to one clearly identified candidate in the public sources checked: Lycia Therapeutics. The company filed an amended registration statement on October 20 with proposed terms for a Nasdaq offering. Fidelity's calendar displays October 22, while Renaissance Capital lists Lycia for the week of October 19 but masks the exact trade date. That difference matters. October 22 is a useful planning signal, not confirmation that pricing or first trading will occur then. [1][2][3]

Renaissance Capital's calendar showed no other U.S. company scheduled to price after this week when checked. That is a report about the calendar's published entries, not proof that no issuer may add, delay, or change an offering. A final prospectus, an exchange notice, or a company announcement could change the picture quickly. [1]

The broader international market is separate. Jio Platforms' large Indian offering is scheduled to open this week, but it is not a U.S. listing and does not belong in a U.S. IPO calendar. Keeping that distinction clear avoids mixing two markets with different regulators, currencies, listing venues, and investor procedures.

What changed in Lycia's filing

Lycia is a South San Francisco biotechnology company developing medicines intended to remove disease-related proteins outside cells. Its technology platform is called LYTAC. The company describes LCA-0061 as a cataLYTAC degrader designed to bind immunoglobulin E, or IgE, and an internalizing receptor so the cell can take up and degrade the target protein. The company says the approach may produce deeper or more durable IgE reduction than blocking IgE activity. That is the company's scientific thesis; it is not yet a demonstrated clinical benefit. [3][4]

The lead program, LCA-0061, is in a Phase 1 study that includes participants with elevated IgE and food allergy. A second IgE program, LCA-0062, is in IND-enabling work. LCA-0321, aimed at Graves' disease, is also in Phase 1. The stages tell us how early the evidence remains: the programs have not established safety and efficacy in large, late-stage trials, and none is an approved product. [3][4]

The amended S-1 identifies Aetna Wun Trombley, Ph.D., as president and chief executive officer. Lycia was founded in 2019. Nobel laureate Carolyn Bertozzi's work helped establish the scientific field behind the company's platform, but an influential scientific origin does not remove the usual clinical, regulatory, manufacturing, and financing risks of developing a new medicine. [3][5]

The proposed offering in plain numbers

Lycia proposes to sell 14.7 million newly issued shares at $16 to $18 each. At the midpoint of $17, that would represent about $249.9 million in gross proceeds. The filing estimates approximately $227.8 million in net proceeds after underwriting discounts and offering expenses, before any exercise of the underwriters' option to buy an additional 2.205 million shares. Final proceeds depend on the price and final deal terms. [3]

At the assumed $17 price, the prospectus estimates 52.1 million shares outstanding immediately after the base offering. Multiplying that share count by the proposed price gives an illustrative post-offering equity value of about $833 million to $938 million across the $16–$18 range. This is a simple calculation from the filing's assumed share count; it is not a company-issued valuation figure, and it excludes the underwriters' option and other potential share issuance. The $17 midpoint implies about $886 million. [3]

The company intends to direct about $80 million toward LCA-0061, $70 million toward LCA-0062, and $90 million toward LCA-0321, with the remainder for other research, development, working capital, and general corporate purposes. Lycia estimates that existing cash, cash equivalents and marketable securities, together with the offering proceeds, would fund its current plan into the second half of 2029. The filing cautions that this estimate relies on assumptions and that the money could be used sooner. [3]

The dilution section deserves a close read. At the $17 midpoint, Lycia estimates pro forma adjusted net tangible book value of $7.15 per share after the offering, producing estimated immediate dilution of $9.85 per share for new investors. In everyday language, the offering price would be well above the accounting value per share calculated after the financing. That comparison is not a forecast of where the stock will trade; it shows how much the IPO price depends on investors' expectations for future research and commercial value. [3]

What the financial statements can and cannot say

Lycia has not generated revenue from product sales. It reported a net loss of $36.5 million in 2025 and $19.2 million in the first six months of 2026. It used $18.1 million of cash in operating activities during that first half. Collaboration revenue fell from $14.9 million in 2024 to $6.7 million in 2025 as work under its Lilly agreement wound down; the filing says that agreement terminated effective February 2026. These amounts are historical, and collaboration revenue is not the same as recurring product sales. [3]

Research spending can move around as trials and manufacturing work progress. Lycia's research and development expense was $17.3 million for the first half of 2026, compared with $25.8 million for the same period of 2025. The prospectus attributes the decline in part to lower direct program and indirect costs. A smaller six-month expense figure should not be read as proof that future development will be cheaper: the company says expenses are expected to rise as it advances clinical programs. [3]

The questions behind the science

The idea is easy to say and difficult to prove: remove enough of a disease-related protein to change the course of an illness, while avoiding harm from affecting other parts of the immune system. Lycia's filings describe an approach designed to send IgE into cells for degradation. In people, investors will want to see whether the drug reaches its target, how long the effect lasts, how patients tolerate repeated dosing, and whether those measurements lead to meaningful improvement in allergic disease. Phase 1 can begin answering safety and dose questions; it cannot settle the commercial case by itself. [3][4]

Lycia's prospectus lists risks familiar to clinical-stage biotechnology firms but unusually important when there is no approved product to support the business: a trial can miss its goals, regulators can require additional evidence, manufacturing can be difficult, and a program can require more money or time than planned. The company may also need additional financing beyond this IPO. A delay could matter because expenses continue while a drug remains in development, and a successful laboratory mechanism is not a substitute for repeatable patient outcomes. [3]

There is also an established treatment landscape. Xolair is an FDA-approved anti-IgE medicine for reducing allergic reactions, including anaphylaxis, that may occur after accidental food exposure. Lycia's proposed distinction is its protein-degradation mechanism, but the company's early-stage program has not yet shown in clinical trials that it will outperform existing options or serve patients who do not benefit from them. The comparison investors should watch is evidence in people, not a theoretical contest between mechanisms. [3][4][6]

What we know

There is a live IPO filing, proposed terms, a proposed Nasdaq symbol, and a specific indication that the company may price this week. The SEC filing gives investors a starting point for examining the science, financial position, dilution, and intended use of proceeds. Lycia's own pipeline page confirms that LCA-0061 is in Phase 1 and LCA-0062 is in IND-enabling activities. [3][4]

What we do not know yet

We do not have a confirmed final price, final share count, completed offering, or official first-trading time. The public calendar sources do not agree on a precise date: one displays October 22, while another leaves the day hidden. We also do not yet have later-stage trial results that could establish whether the proposed mechanism translates into a safe and effective treatment in people.

The next meaningful update is not simply whether the ticker appears on a screen. It is whether Lycia prices, at what terms, and what its final prospectus says about proceeds and share count. Then the first clinical milestones and cash use will matter more than the excitement around opening-day volume. For now, LYCA belongs on the watchlist with its date marked tentative. This report is informational and is not a recommendation to buy or sell securities.

Sources

[1] Renaissance Capital, IPO calendar, checked October 21, 2026: https://www.renaissancecapital.com/IPO-Center/Calendar

[2] Fidelity, IPO calendar, checked October 21, 2026: https://digital.fidelity.com/prgw/digital/offerings/ipocalendar

[3] Lycia Therapeutics, amended Form S-1, filed October 20, 2026: https://www.sec.gov/Archives/edgar/data/1806540/000162828026066381/lyciatherapeutics-sx1a.htm

[4] Lycia Therapeutics, pipeline programs, checked October 21, 2026: https://lyciatx.com/pipeline/programs/

[5] Reuters, “Drug developer Lycia Therapeutics targets $938 million valuation in US IPO,” October 20, 2026: https://www.reuters.com/business/healthcare-pharmaceuticals/drug-developer-lycia-therapeutics-targets-938-million-valuation-us-ipo-2026-10-20/

[6] U.S. Food and Drug Administration, Xolair prescribing information, revised February 2024: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/103976s5245lbl.pdf